Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satralizumab in pediatric AQP4 antibody-positive NMOSD
CTR20255155Phase 3Active
- Sponsor
- Roche
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of satralizumab in neuromyelitis optica spectrum disorder (NMOSD), sponsored by Roche. Started Jan 2026; status: active.
02
Drugs
satralizumab
03
Conditions
neuromyelitis optica spectrum disorder (NMOSD)
Beyond the preview
Go deeper on CTR20255155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255155.